Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
Cagrilintide 與臨床相關的 QTc 延長無關:在健康參與者中的徹底 QT 研究。
Diabetes Obes Metab 2024-09-16
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
Semaglutide在SUSTAIN和PIONEER第IIIa期臨床試驗計畫中的安全性和耐受性。
Diabetes Obes Metab 2023-04-06
Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes.
GLP-1激動劑對2型糖尿病患者死亡率和心律失常的影響。
Int J Cardiol Heart Vasc 2023-05-31
Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
HRS-7535,一種新型口服小分子胰高血糖素樣肽-1受體激動劑,在健康受試者中的安全性、藥物動力學和藥效學:一項階段1、隨機、雙盲、安慰劑對照、單一和多重遞增劑量、以及食物影響試驗。
Diabetes Obes Metab 2024-02-06
Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.
Liraglutide在急性心肌梗塞期間不會增加糖尿病患者的心率。
J Diabetes 2024-01-04
Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.
Semaglutide用於預防心房纖維顫動:系統性回顧與荟萃分析。
Diabetes Metab Syndr 2024-07-02
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
糖尿病和肥胖患者中,胰高血糖素樣肽-1受體激動劑與自殺意念和自我傷害的關聯:一項傾向加權的基於人群的隊列研究。
Diabetologia 2024-08-05
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
Semaglutide 在無已知重大精神病理學的體重管理中的精神安全性:STEP 1、2、3 和 5 試驗的事後分析。
JAMA Intern Med 2024-09-03